

Index

Page numbers with t and f represent tables and figures respectively.

- 1-alkyl-2-azacycloheptanones, isoenhancement concentrations, 281
 - 1-alkyl-2-pyrrolidones, isoenhancement concentrations, 281
 - 1,1'-dioctadecyl-3,3,31',3'-tetramethylindocarbo-cyanine perchlorate (DiI), 341
 - 5-Fluorouracil (5-FU), prodrugs of, 54t–56t
 - 1-hexyl-2-azacycloheptanone (HAZ), 287
 - 1-octyl-2-pyrrolidone (OP), 287
 - 1-O-ethyl-3-buthylcyclohexanol (OEBC), 170
- A**
- Absorption of drugs, physical methods
 - iontophoresis (electric fields), 117
 - phonophoresis (ultrasound), 117
 - Absorption of exogenous chemicals, 304
 - Achilles tendon pain, acute 191
 - Acoustical methods, 320
 - Active barrier creams, 388–393
 - Acyclovir (ACV), 103, 204
 - Acyl and soft alkyl prodrug, 59
 - Acyl and soft alkyl promoieties, 59
 - Alkyl chain length, 22–24, 28, 44–45, 58, 143–144
 - effects of, 279–281
 - Alkyl chains of lipids in SC, 148
 - Alkyl group, 26–27, 44, 57, 59
 - Alkylcarbonyloxymethyl (ACOM), prodrugs
 - 1-ACOM series, 57–58
 - Aluminium chloride salts, for axillary hyperhidrosis, 185
 - Aminopeptidases, 203
 - Trypsin, 203
 - Ammonium glycyrrhizinate (AG), 104
 - Angiotensin-converting enzyme (ACE), 193
 - Animal models
 - iontophoretic delivery
 - antiinflammatory agents, 201
 - cardiovascular agents, 193
 - dermal applications, 193–200
 - miscellaneous nonpeptidic drugs, 201
 - opioids, 200–201
 - protein and peptide drugs, 201–204
 - Animal skin, *in vitro* studies using, 194
 - Animal studies, *in vivo*, 196–197
 - Antibiotics
 - gentamicin, 192
 - penicillin, 192
 - Antidiuretic effect, 197, 202
 - Antifungals, 364
 - Antihistamine drugs, 192
 - Antiinflammatory agents
 - iontophoresis of
 - aspirin, 207
 - diclofenac, 207
 - ketoprofen, 207
 - ketorolac, 207
 - steroids, 207
 - NSAIDs, 207

- Antiinflammatory agents, 201, 207
- Antimuscarinic cationic drug, THP, 101
- Apligraf, 315
- Applicator design
 - ergonomics of delivery system, 75
 - droplet size of spray, 75
 - thumb strength vs. forefinger strength, 75
- Aqueous concentrations of the enhancer, 38–42
 - aqueous enhancer concentration
 - n*-octanol/PBS partition coefficient, 38
- Arbitrary units (AU), 100
- Arginine–vasopressin (AVP), 69
- Assessment of vehicle effects by skin stripping, 299
 - bioequivalence assessments, 302–303
 - corneocyte quantification, 303–304
 - follicular penetration, 304
 - investigation of stratum corneum lipid
 - biochemistry, 300–302
 - investigation of delivery vehicle and skin
 - reservoir effect, 300
 - lateral drug distribution, 303
 - limitations of tape stripping, 304–305
- B**
- Band assignment in the FTIR human SC, 403
- Basal cell carcinomas (BCC), 205
- Bilayer arrays, 362
- Binary chemical enhancers pairs, 328
- Bioengineered-human skin equivalent, 316
- Bioequivalence assessments, 302–303
 - vasoconstriction monitoring, 302
- Biofeedback mechanism, 185
- Bowen's disease, 205
- Branched-chain alkanols as skin permeation enhancers, study of, 23–24
- C**
- Cannabidiol (CBD), 101
- Carbon chain length of fatty acids, effect of
 - skin permeation enhancement, 18–20, 23, 27
 - skin perturbation, 19
- Cardiovascular agents, 193
- Cathodal pulsatile iontophoresis of tranilast, 206
- Ceramide lipid matrix, 281
- Channel-like regions in SC, 260
- Characteristics of solvents
 - nonvolatile solvent, 80
 - volatile solvent, properties
 - lack of toxicity and irritation, 80
 - solvency, 80
 - volatility, 80
- Chemical penetration enhancers (CPEs), 320
- Chemical penetration enhancers, major mechanisms, 18
- Chemical penetration enhancers, structure–activity relationship (SAR)
- fatty acids, 18–22
 - branched versus unbranched fatty acids, 20–21
 - effect of carbon chain length, 18–20
 - geometric isomers, 21
 - number of double bonds, 21–22
 - position of double bond, 21
 - saturated and unsaturated fatty acids, 20
- fatty alcohols, 22–24
 - fatty acids versus fatty alcohols, 24
- pyrrolidones, 26–28
- surfactants, 28
- terpenes, 24–26
- Chemical penetration enhancers, value of, 293–297
- Chemical penetration retardation, 394
- Chemical Warfare Agents (CWAs), 385
- Chemical warfare, 386
 - World War I, 387
 - World War II, 387
- Chemical, biological, radiological, nuclear (CBRN), 385
- Chromatographic analysis of lipids, extracted from
 - human, 301
 - mammalian SC, 301
- Classification of enhancers
 - lipid–protein partitioning (LPP) concept, 9
- Classification of terpenes, 160
 - small-angle x-ray diffraction (SAXD), 165
- Clinical development of penetration enhancer SEPA, 401
 - clinical safety, 412
 - clinical programs, 412–414
 - early successes, SEPA, 406–409
 - nonclinical evaluations of SEPA, 409–412
 - SEPA, 402
 - scientific rationale for designing SEPA, 402–406
- Clinical programs, SEPA, 412
 - EcoNail, 414
 - Opterone[®], 412–414
 - Topiglan[®], 414
- Clinical safety, SEPA, 412
- CLSM devices used for dermatological applications, 341
- CLSM used for tracking liposomal formulations into skin, 341–350

- CLSM
 advantages, 340
 limitations, 340–341
 principles, 339–340
- CLSM, tracking compounds in skin, 335
 Confocal Laser Scanning Microscopy (CLSM),
 336, 339
- CLSM used for tracking liposomal
 formulations into skin, 341–350
- tracking of fluorescence labels into hair
 follicles, 350–351
- Top-Rol[®] dermaroller for substance
 penetration into skin, efficacy of, 351–353
- Colloidal drug delivery systems
 microparticles, 117
 nanoparticles, 117
- Colorimetric index of mildness (CIM), 295
- Common model membrane to represent human
 skin, use of, 322
- Confocal laser scanning micrography (CLSM),
 97, 120, 336, 339–341
 principle of, 339
- Confocal laser scanning (CLS) micrographs,
 98–99
- Confocal microscopy, advantages of, 340
- Consistent thermodynamic conditions for
 enhancer formulations, 322
- Corneocyte quantification, 303–304
 follicular penetration, 304
 lateral drug distribution, 303
 limitations of tape stripping, 304–305
- Corneocytes, 362
- Corneosurfametry, 294
- Corneoxenometry bioassay, 295
- Corneoxenometry, value of, 294
- Correct drug, selection of, 5–6
- Corticosteroid potency, 302
- Corticosteroid skin blanching bioassay, 302
- Corticosterone (CS), 37, 273, 278–279
- Crosslinked hydrogels
 coiled-coil physical interactions, 84
 hydrophobic, 84
 permanent, 83
 reversible, 83–84
- Cryomicroscopy, 362
- Crystalline lipid nanoparticles (CLN), 376
- Current densities (CDs), 69
- Currently marketed transdermal products
 methyl laurate, 320
 oleic acid, 320
 sorbitan monooleate, 320
- CWAs, categories
 cyanides, 386
 incapacitating agents, 386
 lung toxicants, 386
 nerve agents, 386
 tear gases, 386
 vesicants, 386
 vomiting gases, 386
- CWAs, passive barrier creams
 ICD2289, 387–388
 M-5 protective ointment, 387
 T-2 mycotoxin, 387–388
- CWAs, protection
 chemically resistant outer layer of clothing,
 387
 battledress overgarment (BDO), 387
 butyl rubber gloves, 387
 protective mask (M40), 387
 rubber overboots, 387
- CWAs, threat 386
 sulfur mustard and tabun, 386
 sulfur mustard, hydrogen cyanide, 386
 sarin, 386
 yellow rain, tricothecene mycotoxins, 386
- Cyanoacrylate skin surface strippings (CSSS),
 294
- Cyclodextrin, 114
- Cyclosporin A (CyA), 344
- Cystic fibrosis transmembrane conductance
 regulator (CFTR), 184
- Cystic fibrosis, diagnosis of, 184
- D**
- D-Ala 8 CS-betaaminebenzofurazan (Fl-CyA),
 347
- Deionized water, 296
- Delipidized HMS SC, 277
- Delivery and stability of
 LHRH, 204
 nafarelin in human skin, 204
- Delivery of DNA to skin by electroporation, 222
- Delivery of dose
 accurate metering device, 75
 appropriate nozzle, 75
 distance between nozzle, and skin, 75
 droplet size, 75
 spray pattern, 75
- Delivery of genetic material, *in vivo*
 DNA vaccine, 251[†]
 Hepatitis B surface antigen (HBsAg), 251
 naked plasmid DNA, 251
- Dentistry and other oral pathologies,
 191–192
- Dermal applications, 193–200, 204–206
- Dermarollers[®], 336

- Dermatopharmaceutical research
 tape stripping technique, 299
- Dermatopharmacokinetic characterization, 305
- Desmopressin iontophoretic, delivery of, 203
- Diabetes mellitus, 87 ~
- Diclofenac iontophoresis
 clinical use, 207
 side effects
 allergic contact dermatitis, 207
 systemic adverse reaction, 207
- Diclofenac skin permeation, 99
- Diclofenac, 61
- Diethyl *m*-toluamide (DEET), 362
- Different classes of chemicals, 324
- Differential scanning calorimetric (DSC),
 techniques, 19, 99, 164, 403
- Dimethylsulfoxide, DMSO, 402
- Dipalmitoyl phosphatidylcholine (DPPC), 378
- Diphylline liposomes for delivery to skin, 260
- Disadvantage of microemulsions
 skin toxicity, 114
- Dose–response effect of chemical penetration
 enhancers, 295–296
- Drug delivery by phonophoresis, 258
- Drug delivery “push–pull” mechanism, 52
- Drug transport routes through human skin, 4–5
- Drugs
 miscellaneous nonpeptidic, 207
 protein and peptide, 208
- DSC, differential scanning calorimetry, 98
- DTN
 pathways
 nerve agents, 389
 vesicants, 389
 tests
 GP GDL (soman liquid), 390
 pig HDV (sulfur mustard vapor), 390
 rabbit GDV (soman vapor), 390
 rabbit HDL (sulfur mustard liquid), 390
 rabbit VXL (VX liquid), 390
 solid phase microextraction (SPME), 390
 wash, 390
 wipe, 390
- E**
- EcoNail, SEPA-based, antifungal drug, 414
- Econazole, 414
- Effects of, on the *in vitro* flux of methyl
 nicotinamide
 dodecyltrimethylammonium bromide
 (DTAB), 28
 polyoxyethylene fatty ether (Brij 36T™), 28
 sodium lauryl sulfate (SLS), 28
- Efficacy evaluation methods
 decision tree network (DTN), 389
- EGDMA (ethyleneglycol-dimethacrylate), 85
- Elastin, 341
- Electrically assisted technique
 iontophoresis, 13
 metabolic approach, 11
 microneedles, 11
 microscission, 11
 skin electroporation, 13–14
 ultra-deformable liposomes, 14
- Electrically assisted techniques, 13–14
- Electrochemical-enzymatic sensor, 187
- Electromigration, 180–181
- Electroosmosis, 179, 181
- Electroporation and ultra-deformable
 liposomes, 263–265
- Electroporation on skin, 228–230
 biophysical, 231
 histological, 231
 macroscopic barrier, 232
 skin irritation, 232
- Electroporation, 221, 320
 electroporation on skin, effects of, 228
 factors influencing percutaneous penetration
 enhancement, 224–228
 electrical parameters, 224–226
 physicochemical factors, 226–228
 percutaneous penetration enhancement
 mechanisms, 222
 creation of new pathways, 223
 expansion of preexisting pathways, 223
 thermal effects due to electroporation, 224
 potential applications, 232–234
- Electroporation, application of
 high voltage electric pulses of very short
 duration, 222
- Electroporation, future prospects, 234
- Electroporation, *in vitro* percutaneous
 penetration enhancement of drugs
 using, 233t
- Electroporation, potential applications
 gene delivery, 232
 topical drug delivery, 232
- Electroporation, thermal effects, 224
- EMLA cream, 185
- Encapsulation structures
 drug delivery vehicles, 375
 liposomes, 375
 lipid complexes, 375
 nanocapsules, 375
 nanospheres, 375
 submicron emulsions, 375

- nanocapsules, preparation of, 375
 - emulsification–diffusion technique, 376
 - solvent displacement procedure, 376
 - Enhancer potency, 272
 - Enhanced skin penetration, carriers, 117
 - microparticles, 118
 - nanoparticles, 118–119
 - Enhanced skin penetration, PNBCA
 - nanocapsules carrier
 - indomethacin, 119–122
 - Enhanced skin permeation using ethosomes, 95
 - definition, structure, and main properties of ethosomes, 96–97
 - mechanism of skin permeation enhancement by means of ethosomes, 97–99
 - various aspects of ethosomal delivery system, 99–105
 - efficiency to enhance drug permeation into and through the skin, 99–104
 - safety evaluation *in vitro*, in animals and in human, 104
 - stability and manufacture, 104–105
 - Enhancement factors, CS, 287
 - Enhancement of delivery into stratum corneum, 76–79
 - available area, 78
 - increase in thermodynamic activity of drug, 78
 - sebum, 77–78
 - topology of skin surface, 76–77
 - Enhancement of delivery with transdermal sprays, 74
 - enhancement of delivery of dose to skin, 75–76
 - control of area, 75–76
 - metering valves, 75
 - spray pattern and droplet size, 75
 - enhancement of delivery into stratum corneum, 76–79
 - available area, 78
 - increase in thermodynamic activity of drug, 78
 - sebum, 77–78
 - topology of skin surface, 76–77
 - enhancement of permeation through skin, 79
 - effect on lipid arrangement, 79
 - extraction of lipids, 79
 - selective extraction of cholesterol, 79
 - solvent drag, 79
 - enhancement of bioavailability, 80
 - evaporation of volatile component of vehicle, 78
 - solvents and enhancers delivery,
 - characteristics of, 80–81
 - nonvolatile solvent, 80
 - penetration enhancer, 81
 - volatile solvent, 80
 - increasing solubility of drug in stratum corneum, 78–79
 - Enhancement of permeation through skin
 - solvent drag, 79
 - ethanol, 344
 - Enhancer concentrations in SC intercellular lipids, 42–43
 - Enhancing transdermal drug delivery, 5–7
 - Epiderm™, 313–314
 - Epidermal architecture, 312
 - EpidermFT™, 315
 - Epidermis–dermis combination (D/E), 275
 - Epinephrine solution, 205
 - Episkin™, 315–316
 - Equilibrium partitioning domain, 286–287
 - Equilibrium partition enhancement of ES into SC intercellular lipids, 286
 - Equilibrium permeant partitioning into SC intercellular lipids, 278
 - Erectile dysfunction (ED), 412
 - ES transdermal penetration, 278
 - Essential oils and terpenes, 159–160
 - improving permeation enhancement ability of terpenes, 163–165
 - mechanism of action of terpenes, 165–168
 - structural classification, 160–161
 - structure–activity relationships, 162–163
 - terpene derivatives as enhancers, 168–171
 - Estradiol (ES), 273, 278
 - Ethosomal delivery system
 - enhanced *in vitro* delivery of molecules with diverse chemical properties, 100
 - safety evaluation *in vitro*, in animals and in human studies, 104
 - stability and manufacture, 104–105
 - Ethosomes, in transdermal delivery, 100
 - Ethylene–vinyl acetate (EVA) matrix, 90
 - E-TRANS electrotransport technology, 189
 - E-trans technology, 13
 - E-TRANS[®] Fentanyl HCl, 189–190
 - Eyegate device, 192
- F**
- Faraday's law, 182
 - Fatty acid esters, 146–147
 - Fatty acids and vehicles as penetration enhancers for different drug molecules, 140t

- Fatty acids
 polyunsaturated fatty acids, 21
 saturated fatty acids, 18–19, 145, 153
 unsaturated fatty acids, 18–20
- Fatty acids, 144–148
 carbon chain length of fatty acids, effect of, 145
 chemical modification of drugs with fatty acids, 147–148
 double bonds in unsaturated fatty acids, position of, 146
 fatty acid esters, 146–147
 saturated vs. unsaturated fatty acids, 145–146
- Fatty alcohols and fatty acids on the skin
 permeation, 137
 fatty acids, 144–148
 fatty alcohols, 139–144
 formulation considerations, 150–152
 penetration enhancement, mechanism of, 148–150
 skin irritation potential, 152–153
- Fatty alcohols and fatty acids on the skin, 137–153
- Fatty alcohols as skin penetration enhancers, 138t
- Fatty alcohols or acids reported as skin penetration enhancers in the patent literature, 141t
- Fatty alcohols, 139–144
- Fick's law, 52–53, 129, 363
- Fluorescence detector, 336
- Fluorescent SLN (F-SLN), 126
- Fluorescently labeled polypeptide, bacitracin (FITC-Bac), 98–99, 101
- Follicle orifices, 304
- Follicle stimulating hormone (FSH), 203
- Follicular apparatus, parts
 acroinfundibulum, 304
 infrainfundibulum, 304
- Follicular penetration process, 304
- Food and Drug Administration (FDA), 387
- Formulation considerations, 150–152
 enhancer configuration in TDS, 150–151
 fatty alcohols and acids in transdermal patches, 151–152
- Fourier transform infrared spectroscopy (FTIR), 148, 166, 403
- Franz diffusion cells (FDCs), 321
- G**
- Generally recognized as safe (GRAS), 404
- GH-releasing peptide (GHRP), 204
- GlucoWatch[®] Biographer, 187–188
- Glycerol, 295
- Growth hormone (GH) deficiency, 204
- Growth hormone releasing hormone (GHRH), 204
- H**
- Hair follicles, 102, 118, 153, 304, 386, 405
- Hair growth cycle, 304
- Hairless mouse skin (HMS), 273
- Herpes Simplex Virus (HSV), 204
- Hexapeptide, 204
- High density polyethylene (HDPE), 379
- High pressure homogenization (HPH), 126
 cold homogenization, 127
 hot homogenization, 127
- High shear homogenization, 126
- ultrasonic dispersion, 126
- High-pressure liquid chromatography (HPLC), 321
- High-velocity particles system
 powderject system, 8
 intraject system, 8
- HMS SC Delipidization, 276–277
- HMS stratum corneum (SC) lipid composition, 273
- Home-use iontophoretic devices, 185
- Homogeneous, hydrogels, 84
- hPTH, effect on bones
 anabolic, 203
 catabolic, 203
- Human cadaver skin *in vitro*, 202
- Human calcitonin delivery in rats by iontophoresis, 203
- Human immunodeficiency virus-type 1 (HIV-1)
- Human nail, 414
- Human parathyroid hormone (hPTH), 203, 225
- Human skin, *in vitro* studies using, 195
- Human studies *in vivo*, 198–199
- Human studies
 dermal applications
 acyclovir, 204
 antiviral drugs, 204
 antiviral idoxuridine, 204
 Ara-AMP, 204
 electroosmosis, 204
 epinephrine, 204
 Herpes Simplex Virus (HSV), 204
 HSV vesicular orolabial lesions, 204
 human skin, 204
 lidocaine, 204
 methylprednisolone sodium succinate, 204
 nude mouse skin, 204
 postherpetic neuralgia

- iontophoretic delivery
 - antiinflammatory agents, 207
 - dermal applications, 204–206
 - miscellaneous nonpeptidic drugs, 207
 - opioids, 206
 - protein and peptide drugs, 208
 - Humidity of environment, 67
 - Hydrocortisone (HC), 273, 278
 - Hydrogel vehicles for hydrophilic compounds, 83
 - applications of hydrogels, 87–91
 - hydrogels, 89–90
 - transdermal patches, 90–91
 - hydrogels, 83–87
 - physical and chemical properties, 84–87
 - Hydrogels, 83–87, 89–90
 - Hydrogels, types of
 - copolymers, 84
 - homopolymer, 84
 - Hydrogels, use of
 - biomedical applications, 83
 - pharmaceutical formulations, 83
 - Hydrogen bond donor group, 57–58
 - Hydrophilic gels for biological use
 - poly(2-hydroxyethylmethacrylate) (PHEMA)
 - in contact lenses, 83
 - Hydrosoluble drugs
 - as methotrexate (MTX), 90
 - Hypoglycemia, 187
 - Hypogonadal male, uses
 - first-generation testosterone cream, 413
 - opertone cream, 414
 - second generation testosterone cream, 414
 - SEPA hydroalcoholic gel, 414
 - Hypogonadism, symptoms, 412
 - decreased sexual desire, 413
 - fatigue, 413
 - impotence, 413
 - low motivation, 413
 - mood depression, 413
 - osteoporosis, 413
 - regression of secondary sexual characteristics, 413
- I**
- In vivo* gene transfer and genetic immunization, 251
 - Increase in thermodynamic activity of drug
 - choice of nonvolatile solvent, 78
 - evaporation of volatile component of vehicle, 78
 - increasing solubility of drug in stratum corneum, 78–79
 - Infrared spectroscopic techniques, 19
 - Infrared spectroscopy, 165
 - Ingress of xenobiotics, 362
 - Inorganic materials
 - layered double hydroxides (LDHs), 378
 - miconized TiO₂, 377
 - Insertion of intravenous (IV) catheters, 186
 - Insertion of microneedles into skin,
 - mechanics of
 - measurement, 245
 - needle fracture force, 244
 - prediction of insertion force, 244–245
 - ratio of fracture force to insertion force, 246
 - INSIGHT screening, 324
 - applications of, 327–329
 - overview of, 322–323
 - INSIGHT with FDC, validation of, 327
 - Intelligent biomaterials, 84
 - Intercellular lipid bilayers, 69–70, 222, 224
 - Intercellular lipid domain of SC, 99
 - Intercellular lipoidal, 272
 - pore pathway transport, 272
 - Inter-corneocyte pathways, 99
 - Investigational New Drug (IND), 387
 - Iontophoresis and electroporation on SC, effect of, 263
 - Iontophoresis in drug delivery, 258
 - Iontophoresis successes
 - GlucoWatch[®] Biographer for glucose monitoring, 208
 - ionsys fentanyl delivery system, 208
 - LidoSite[®] device for topical lidocaine anesthesia, 208
 - Iontophoresis
 - mechanisms, 179–181
 - practical considerations, 181–184
 - Iontophoresis
 - delivery of peptides, 258
 - delivery of proteins, 258
 - positive ions transport, 258
 - Iontophoresis, clinical applications, 177
 - existing therapeutic applications of
 - iontophoresis, 184–192
 - FDA approved applications, 184–190
 - other applications of iontophoresis *in vivo*, 190–192
 - potential candidates for iontophoretic delivery, 193–208
 - animal models, 193–204
 - human studies, 204–208
 - principles of iontophoresis, 179–181
 - mechanisms, 179–181
 - practical considerations, 181–184

Iontophoresis, future challenges
 control of drug dose, 208
 designing iontophoretic patch system, 209
 noninvasive peptide delivery, 208
 Iontophoresis, future challenges, 177
 Iontophoresis, local anesthesia of ear by, 186
 Iontophoresis, treatment of skin cancer
 Iontophoretic delivery of ALA, 205
 Iontophoretic delivery of cisplatin
 BCC, 205
 SCC, 205
 Iontophoretic delivery
 of fentanyl HCl (Ionsys), 190
 of LHRH, 203
 Iontophoretic devices for drug delivery, 222
 Iontophoretic transport, pathways of, 258–259
 Irritation, 114
 Isopropyl myristate (IPM), 53

J

Jet injection, 320

K

Kaposi's sarcoma, treatment of
 human immunodeficiency virus-positive,
 205
 Keratin, 340, 362
 Keratinization, 70
 Keratinocytes of skin, 232
 Keratinocytes, 312
 Ketoprofen, 61
 Kinetics of transdermal drug delivery
 dermatopharmacokinetic analyses, 300

L

La Place equation, 133
 Lacquer–nail interface, 414
 Layer of sebum, 77
 Leuprolide acetate *in vivo*, 328
 Leutenizing hormone releasing hormone
 (LHRH), 11, 328
 Lewisite exposure, 386
 LHRH, delivery of
 hypogonadism, 203
 hypogonadotropic, 203
 Lidocaine delivery, 185–187
 Lidocaine iontophoretic device, second-
 generation, 186
 LidoSite[®], 186
 Linear dose–effect responses, 295
 Linoleic acid, 146
 Lipid layers of liposomes, 79
 Lipid monomers, 260

Lipid–protein partitioning theory, 18; *see also*
 LPP theory
 Lipophilic drug testosterone, 96
 Lipophilic environment, 77
 Lipophilic moiety, 37, 44
 Lipophilicity, 281
 Liposomes for delivery of drugs to skin, 95
 Liposomes
 dermal penetration, 260
 transdermal delivery system, advantages of,
 259–260
 L-Menthoxyp propane-1,2-diol (MPD), 169
 Localized dissipation regions (LDRs), 224
 Localized transport region (LTR), 223
 LPP theory, 18
 Luteinizing hormone (LH), 203
 Luteinizing hormone-releasing hormone, 203

M

Macromolecular hydrophilic drug
 inulin, 324–325
 mannitol, 324–325
 Macroroutes of drug penetration
 across stratum corneum, 1
 through hair follicles, 1
 through sweat ducts, 1
 Macroscopic SC intercellular lipid phase, 46
 Magnusson and Kligman maximization test
 design, 407
 Major routes of drug molecules, through
 stratum corneum
 intercellular route, 18
 transcellular route, 18
 Male hypogonadism (testosterone deficiency),
 412
 Malignant hypercalcemia, 203
 Maximum fluorescence intensity (MaxFI), 100
 Mechanism of action of terpenes, 165–168
 Mechanism of penetration enhancement,
 148–150
 Mechanism of transdermal drug delivery by
 electroporation, 222–224
 Mechanistic studies of permeation enhancers,
 271
 methods, 273–278
 animal model, 273
 partition experiments, 276–278
 transport experiments, 273–276
 results and discussion, 278
 alkyl chain length, effects of, 279–281
 branched alkyl chain, effects of, 283–285
 hydrocarbon chain carbon–carbon double
 bond, effects of, 281–283

- isoenhancement concentrations and enhancer, effects, 278–279
 - polar head functional groups, effects of, 281
 - Mesylate salt, 143
 - Met-enkephaline, 204
 - Metered dose transdermal spray, 10, 74, 76–78, 81
 - Metering valves
 - inhalation solution, 75
 - nasal spray, 75
 - Methotrexate delivered by iontophoresis
 - treatment of recalcitrant psoriasis, 206
 - Methyl nicotinate (MN), 101
 - application of, 104
 - Microemulsion, effects on stratum corneum, 114
 - Microemulsions, role of, 109
 - topical drug delivery, 111–114
 - in vivo* results, 114
 - irritation, 114
 - microemulsions and drug permeability, 112–114
 - solubilization of drugs by microemulsions, 111–112
 - Microemulsions, types of
 - bicontinuous, 111
 - oil-in-water (O/W), 111
 - water-in-oil (W/O), 111
 - Microfabrication technology, microneedles
 - lithography, 240
 - plasma etching, 240
 - Microneedles, 239
 - microneedle fabrication, 240
 - hollow metal microneedles, 244
 - hollow silicon microneedles, 244
 - solid metal microneedles, 241
 - solid polymer microneedles, 242–244
 - solid silicon microneedles, 240–241
 - microneedle properties, 244
 - avoidance of pain, 246
 - insertion into skin, 244–246
 - transdermal delivery using microneedles, 247
 - in vitro* delivery of model compounds, 247–249
 - in vivo* delivery of genetic material, 251–252
 - in vivo* delivery of peptides and proteins, 249–250
 - Microneedles, 320
 - Microneedles, future prospects
 - fabrication methods, 252
 - optimal design of microneedles, 252–253
 - strengths and limitations of microneedles
 - Microparticles for enhancing skin penetration, 118
 - PLGA microparticles, 118
 - poly(DL-lactic-co-glycolic acid) (PLGA), 118
 - topical delivery of drugs
 - 5-fluorouracil, 118
 - retinol, 118
 - Microscopic array of needles, 240
 - Military perspectives in chemical penetration
 - retardation, 385
 - active barrier creams, 388–393
 - efficacy evaluation methods, 389–390
 - results and conclusions, 391–393
 - passive barrier creams, 387–388
 - transdermal chemical inhibitors, 393–394
 - Military, operations
 - CBRN, 385
 - NTA, 385
 - TIC, 385
 - TIM, 385
 - Minoxidil, 407
 - Miscellaneous drugs, nonpeptidic
 - alniditan, 199t, 207, 233t
 - iontophoretic delivery of R-apomorphine, 207
 - Moisturizing chemicals, 70
 - Molecular blockers, effects of
 - photoallergic, 131
 - phototoxic effects, 131
 - Myringotomy, 186
- N**
- N*-(lissamine rhodamine B sulfonyl)-diacylphosphatidylethanolamine (Rho-PE), 337
 - N*-acetyl-L-cysteine (NAC), 295
 - salicylic acid (SA), 295
 - urea, 295
 - Nanoparticles for enhancing skin penetration, 118–119
 - Nano-scaled drug carriers
 - liposomes, 336
 - micelles, 336
 - nanospheres, 336
 - Naproxen, 61
 - Nature and structure of skin, 362–363
 - New Drug Application (NDA), 387
 - New threat agent (NTA), 385
 - Noninvasive glucose monitoring, 187

- Nonmelanoma skin tumors, 205
- Nonpeptidic drugs
iontophoretic delivery of ropinirole, 201
- Nonsteroidal antiinflammatory drugs (NSAIDs), 53, 117
- Nonvolatile solvents
estradiol, 80
octisalate, 80
padimate O, 80
testosterone, 80
- NSAIDs, agents
indomethacin, 201
ketoprofen, 201
naproxen, 201
salicylic acid, 201
- O**
- Occlusive effect of SLN on skin, 132
SLN on human skin, 133
- Octreotide, 204
- Octyl methoxycinnamate (OMC), 376
- O-Ethylmenthol (MET), 169
- Oleic acid, 146
- Oligonucleotides, 251–252, 328
- OMC-nanocapsule-gel, 376
- Onychomycosis treatment, 414
- Ophthalmology, 186, 192
- Opioids, 200–201, 206
iontophoretically postsurgery, 206
morphine HCl, 206
patient-controlled analgesia (PCA), 206
- Orcel[®], 315
- Organophosphorous (OP), 386
- Otorhinolaryngology, 192
- Outermost layers of skin, stratum corneum (SC), 221, 374
- Out-of-focus light, 339
- o/w emulsion, 376
- Oxybenzone, 375
- P**
- Paget's disease, 203
- Palmoplantar hyperhidrosis, 185
- Parenteral nutrition emulsions, 126
- Parkinsonian syndrome, 101
- Partition coefficient systems
n-alkanol/PBS, 40
n-decanol/PBS, 38–39
n-hexane/PBS, 38–40
n-hexanol/PBS, 38–39
n-octanol/PBS, 38, 40, 47
- PC cream, 131
- PC-cholate vesicles, 261
- Penetration enhancement by skin hydration, 67–70
- Penetration enhancer assessment by
corneoxenometry, 293
corneoxenometry, 294–295
corneoxenometry and organic solvents, 296
dose–response effect of chemical penetration enhancers, 295–296
- Penetration enhancer classification
drug transport routes through human skin, 4
enhancing transdermal drug delivery, 5
chemical potential adjustment, 6
eutectic systems, 7
interactions between drug and vehicle, 5
ion pairs and complex coacervates, 7
selection of correct drug or prodrug, 5
- electrically assisted techniques, 13
electroporation, 13
iontophoresis, 13
magnetophoresis, 14
photomechanical wave, 14
radio waves, 14
ultrasound (phonophoresis, sonophoresis), 13
- stratum corneum bypassed or removed, 11
follicular delivery, 13
microneedle array, 11
stratum corneum ablated, 11
stratum corneum modified, 8
chemical enhancers, 9
hydration, 8
vesicles and particles, 7
high-velocity particles, 8
liposomes and analogs, 7
- Penetration enhancer classification, 4–14
- Penetration enhancers, 26
- Penetration enhancers, action of
lipid action, 10
partitioning promotion, 10–11
protein alteration, 10
- Penetration retarders, 378
- Peptide drugs
LHRH analog leuprolide, 208
- Percutaneous absorption of CyA, 344
- Percutaneous absorption of drugs, 117, 148, 222, 26
- Percutaneous penetration, methods of
electron microscopy, 336

- fluoromicrography, 336
 microdialysis, 336
- Permeation enhancement results,
 microemulsion, 113
- Permeation enhancement through skin, 29
- Permeation enhancers, chemical structures of,
 39f
- Permeation enhancers, SC lipoidal pathway
 1-butyl-2-pyrrolidone, 278
 1-hexyl-2-pyrrolidone, 278
 1-octyl-2-pyrrolidone, 279
- Permeant partitioning into transport rate-
 limiting domain, 278
- pH of formulation, 227–228
- Phosphate buffered saline solution (PBS), 37,
 273, 345
- Phosphatidylcholine (PL), 98
- Photodynamic therapy (PDT), 205
- Photon correlation spectroscopy (PCS), 126
- Photosensitizer, protoporphyrin IX (PpIX), 205
- Photosensitizer, protoporphyrin IX,
 measurement of
 fluorescence, 205
 phototoxicity, 205
- Physical medicine, 191
- Physical properties of organic particulate UV-
 absorbers, 377
- Physically cross-linked chitosan hydrogels as
 topical vehicles applications of, 87
 for hydrophilic drugs, 87
 hydrogels, 89–90
 transdermal patches, 90–91
- Physicochemical factors
 charge of permeant, 226
 electrolytes, 228
 molecular size, 226
 temperature, 226
- Pilocarpine, 184
- Pinhole, 336
- Plaques of SC, 305
- Plasma levels of
 follicle stimulating hormone (FSH), 203
 luteinizing hormone (LH), 203
- Pluronic F-127 gel, 119
- PNBCA nanocapsules, 119–122
- PNBCA nanocapsules, carrier of indomethacin,
 119
- Polar functional groups, effects of, 281
- Poly(ethylene glycol) (PEG), 86
- Poly(n-butylcyanoacrylate) (PNBCA), 119
- Polyalkylcyanoacrylate nanocapsules, 119
- Polyoxyethylene (POE), 61
- Polytetrafluoroethylene (PTFE), 387
- Polyunsaturated fatty acids, types of
 arachidonic acid, 21, 139, 145, 146, 153
 linoleic acid, 19–21, 145, 148
 linolenic, 21–22, 148–149
- Porous hydrogels, 84
- Position of double bonds in unsaturated fatty
 acids, 21
- Postherpetic neuralgia (PHN), 204
- Postmenopausal osteoporosis, therapy of, 203
- Potent insecticides, 362
- PpIX
 fluorescence, 205
 phototoxicity, 205
- Preclinical development of penetration
 enhancer SEPA, 401–414
- Preiontophoresis, 205
- Preparation of solid lipid nanoparticles, 126–127
- Process of electroosmosis, 258
- Prodrugs in penetration enhancement, role of,
 51
 acyl vs. soft alkyl promoieties, 54
 basis for prodrugs as penetration enhancers,
 52–53
 mechanisms for penetration enhancement,
 54–62
 push versus pull mechanisms for penetration
 enhancers, 52
- Prodrugs of
 diclofenac, 56, 62
 5-FU, 55, 57
 levonorgestrel, 59–60t
 indomethacin, 56, 60–61t
 ketoprofen, 56, 62t
 naproxen, 56, 60t–62t
- Propylene carbonate, 295
 hydroxypropylcellulose, 295
 butylhydroxytoluene, 295
 ethanol, 295
- Propylene glycol, 408
- Protein and peptide drugs, 201–204
- Protein and peptide drugs, iontophoretic
 delivery of insulin
in vitro, 201
in vivo, 201
- Q**
- QSARs, 328
- Quantitative descriptions of structure–activity
 relations, 328
- Quantitative structure
 enhancer concentrations based on aqueous
 concentrations of the enhancer,
 38–42

Quantitative structure (*cont'd*)

- enhancer concentrations based on stratum corneum intercellular lipids, 42–45
- microenvironment of the site of enhancer action, 45–46
- transdermal drug delivery, 46–47

R

- Random pairing of CPEs, 328
- RBC acetylcholinesterase (AChE) activity, 388
- Red blood cell (RBC), 388
- Reducing skin absorption, possibilities, 364
- Relative index of irritancy (RII), 295
- Retardation strategies for sunscreen agents, 373
 - cyclodextrins and photostability, 374–375
 - encapsulation structures, 375–376
 - inorganic materials, 377–378
 - physical properties of organic particulate UV-absorbers, 377
 - penetration retarders, 378
 - Transcutol[™], 375
 - vehicle effects, 379
- Retarding penetration, fundamentals of, 361
 - effects of chemical structure, 364–366
 - formulation effects, 367–368
 - nature and structure of skin, 362–363
 - physicochemical determinants, 363–364
 - reducing skin absorption, 364
- Rheumatoid arthritis (RA), 129
 - of knee, 191
- Rhodamine red dihexadecanoyl glycerophosphoethanolamine (RR), 99
- Root canal surgery, 186
- RR from ethosomes, application of
 - hydroalcoholic solution, 99
 - liposomes, 99–100

S

- SAR, 18, 366
- Saturated fatty acids
 - branched hydrocarbon chain, 139
 - linear hydrocarbon chain, 139
- Saturated long chain fatty acids, application of
 - lauric acid [C12], 19, 24, 139, 313, 324
 - myristic acid [C14], 19, 142, 145, 150
 - stearic acid [C18], 20, 87, 89, 143
- SC
 - different pathways
 - parallel lipoidal, 36–37, 275
 - pore pathways, 36–37
 - intercellular lipid domain, 37, 43, 46, 283, 286
 - intercellular lipid phase, 286
 - intercellular lipids, 43, 47, 143, 279, 285–286, 288, 375
 - lipid bilayers, 96
 - lipid lamellae, 38, 41–42, 46, 144, 286
 - lipids, components of
 - ceramides, 300
 - cholesterol, 300
 - free fatty acids, 300
 - rate-limiting, 286
- Scanning and freeze-fracture electron micrographies (SEM and FFEM), 96
- Scanning electron micrograph (SEM), 96, 103, 120, 403–404
- Scientific rationale for designing SEPA, 402
 - experimental data, 403–404
 - how formulation affects skin permeation performance, 405–406
 - physical–chemical characteristics of SEPA, 404–405
- SCOPE formulations, 10–12
- Screening of chemical enhancers
 - in vitro*, 320
 - in vivo*, 320
- Screening of Transdermal Penetration Enhancers, 319–329
- Sebaceous glands, 362
- Sebum, 77–78
- Selected key clinical safety and efficacy studies, description of, 412
- SEPA hydroalcoholic gel
- SEPA on human SC, effects of, 404
- SEPA testing program, 410–411
- SEPA vehicle, 407
- SEPA
 - clinical programs, 412
 - EcoNail, 414
 - Opterone[®], 412–414
 - Topiglan[®], 414
 - clinical safety, 412
 - clinical use, 407–409
 - early successes
 - in vitro* absorption of indomethacin, 406
 - in vivo* percutaneous absorption, 406
 - scalp hair growth in balding stump-tail macaque, 407
 - nonclinical evaluations, 409–412
- SEPA-enhanced topical testosterone cream, Opterone, 412
- SERPACWA
 - active topical skin protectant (aTSP), 389–390
 - against Soman, 391

- against Sulfur Mustard, 392
- ICD2837, 394
- ICD2289, 387–388
- Site-specific drug delivery, 117
- Skin alternatives for testing percutaneous penetration, use of, 311
- types of cultured skin models, 313–316
 - epidermal models, 313–314
 - full-thickness models, 315–316
 - skinEthic, 314
- Skin blanching, 302–303
- Skin Exposure Reduction Paste Against Chemical Warfare Agents, 387–388
- Skin grafting, 312
- Skin hydration, 67
- Skin impedance for enhancers
 - lipid extraction, 326
 - lipid bilayer fluidization, 326
- Skin impedance–permeability correlation
 - different classes of chemicals, 324
 - INSIGHT screening, 324
 - macromolecular hydrophilic drug
 - inulin, 324–325
 - mannitol, 324–325
 - skin impedance for enhancers
 - lipid extraction, 326
 - lipid bilayer fluidization, 326
- Skin Integrity Function Test (SIFT), 323
- Skin irritation potential, 152–153
- Skin layers
 - dermis, 362
 - stratum corneum, 362
 - viable tissue, 362
- Skin models, nonhuman animal skins
 - cultured skin alternatives, 312
 - hairless mouse skin, 312
 - human cadaver skin, 312
 - pig skin, 312
 - rodent skin, 312
- Skin models, uses of
 - evaluation of dermal irritancy of new investigational drugs, 312
 - evaluation of dermal irritancy of new investigational cosmetics, 312
 - evaluation of permeation, 312
 - evaluation of phototoxicity, 312
- Skin necrosis, 294
- Skin penetration enhancement, classes, 293
 - lipid fluidizer type, 294
 - solvent type, 294
- Skin penetration enhancers, 138
 - fatty acids, 144–148
 - fatty alcohols, 139–144
- Skin permeability to various drugs
 - fatty acids, 320
 - fatty esters, 320
 - nonionic surfactants, 320
 - anionic surfactants, 320
- Skin permeation enhancement, 99
- Skin permeation enhancers, types of
 - alkanes, 18
 - amides, 18
 - azone and its derivatives, 18
 - cyclodextrins
 - esters, 18
 - fatty acids, 20–21
 - fatty alcohols, 18
 - pyrrolidones, 18
 - sulfoxides, 18
 - surfactants, 18
 - terpenes, 18
 - urea and its derivatives, 18
- Skin permeation performance, formulation
 - affects, 405–406
- Skin retention vehicles, 376
- Skin stripping methodologies
 - chemical penetration into skin, 300
 - chemical permeation through skin, 300
 - chemical elimination from skin, 300
 - clinical parameters, 300
 - pharmacodynamic parameters, 300
- Skin stripping, investigation of, 299
 - delivery vehicle and skin reservoir effect, 300
 - stratum corneum lipid biochemistry, 300–302
- Skin transport model, 275
 - donor chamber, 275, 278, 281
 - receiver chamber, 275, 281
- SLA:PP (Sodium Laureth Sulfate:Phenyl Piperazine), 328
- SLN, delivery of Prednicarbate (PC)
 - in vitro*, 131
 - in vivo*, 131
- SLN, topical delivery of triptolide, 129
- Soft enhancement of percutaneous absorption (SEPA[®]), 402
- Solar radiation, 373
 - skin pathologies
 - cutaneous photoageing, 373
 - dendritic keratitis, 373
 - skin cancer, 373
- Solid lipid nanodispersions, 126
- Solid lipid nanodispersions for topical delivery, 128–131
- Solid lipid nanoparticle and microemulsion for topical delivery of triptolide, 129–130
- Solid lipid nanoparticles (SLN), 68, 125, 132, 376

- Solid lipid nanoparticles for topical delivery, 125
- characterization of SLN, 127–128
 - solid lipid nanoparticles, preparation of, 126
 - emulsification or vaporization method, 127
 - high pressure homogenization, 126–127
 - high shear homogenization and ultrasonic dispersion, 126
 - microemulsion, 127
 - SLN incorporation and release of drug, 128
 - SLN for topical delivery, 128–131
 - SLN as a novel carrier system for sunscreens, 131
 - in vitro* occlusion of SLN, 132–133
 - occlusive effect of SLN, 132
 - SLN *in vivo* occlusion, 133–134
- Solid state of the lipid, 131
- Somatostatin, 204
- Spaces between corneocytes, 77
- Squamous cell carcinomas (SCC), 205
- Square wave pulses, 224–225
- Stability of LHRH and Nafarelin in human skin, 204
- Steroidal permeant
- CS, 287
 - HC, 287
 - ES, 287
- Straight-chain compounds
- long-chain (C12–C24), 138
 - medium chain (C6–C10), 138
- Stratum corneum (SC) by CyA, 346
- Stratum corneum (SC) hydration by exogenous chemicals, 69–70
- occlusion, 68–69
- Stratum corneum (SC), 36, 67, 95, 138, 273, 346;
see also, SC
- Stratum corneum bypassed or removed, 11–13
- Stratum corneum lipids, 366
- Stratum corneum modified, 8–11
- Structure–activity relationship (SAR), 10, 18, 74, 162, 366
- Sunscreen nanocapsules, 376
- Sunscreen, complexation
- butyl-methoxydibenzoylmethane, 374–375
 - hydroxypropyl- β -cyclodextrin, 374–375
 - sulfobutylether- β -cyclodextrin, 374–375
- Superficial epidermal layer, 67
- Superficial layers of stratum corneum, 78
- Surfactants, classification of
- anionic, 28
 - cationic, 28
 - nonionic 28
 - zwitterionic 28
- Swelling behavior of hydrogels, 84
- Synergistic combinations of penetration enhancers (SCOPE), 10–12
- Synthesis of cholesterol, 79
- ## T
- Tap water delivery for the treatment of hyperhidrosis, 184–185
- Tape stripping of human stratum corneum, 300, 304
- Tap-water iontophoresis, 185
- Techniques for routine measurements of particle size
- laser diffraction (LD), 128
 - photon correlation spectroscopy (PCS), 128
- Terpenes, types of
- alcohol, 24
 - cyclic ether terpenes, 24
 - hydrocarbon, 24
 - ketone, 24
 - oxide, 24
- Tesa strip test, 129, 133
- Testosterone transdermal delivery
- oral testosterone, 413
 - serum testosterone, 413
 - transdermal testosterone, 413
- Therapy of acromegaly, 204
- Thermal poration, 320
- Thermodynamic activity of drug, 112
- Thermogravimetric analysis (TGA), 165
- Topical delivery of
- 5-fluorouracil (5-FU), 57
 - 1-alkylcarbonyloxymethyl prodrugs of 5-fluorouracil (5-FU), 58
 - NSAIDs, 62
- Topical drug delivery, microemulsions
- hydrophilic drugs, 111
 - lipophilic, 111
- Topical testosterone products
- buccal adhesive tablet, 413
 - topical testosterone gel, 413
- Topiglan
- moderate-to-severe ED, 414
 - mild-to-moderate ED, 414
- Topiglan, use of
- male erectile dysfunction, 414
- Topology of skin surface, 76–77
- Toxic industrial chemical (TIC), 385
- Toxic industrial material (TIM), 385

- Transcutol[®] CG
 diethylene glycol monoethyl ether,
 375
- Transdermal delivery of enkephalin *in vitro*,
 261
- Transdermal delivery of estradiol in
 postmenopausal women, 74
- Transdermal delivery of neutral molecules,
 258
- Transdermal delivery using microneedles
in vitro delivery of model compounds,
 247–249
in vivo delivery of peptides and proteins,
 249–250
in vivo delivery of genetic material, 251–252
- Transdermal drug delivery transport
 chemical, 240
 electrical, 240
 ultrasonic, 240
- Transdermal drug delivery
 advantages of, 87–89
 disadvantage of, 89
 current status, 91
 future prospects, 91
 past progress, 91
- Transdermal drug delivery, 46–47
- Transdermal iontophoretic, delivery of
 calcitonin, 14, 197
 salmon calcitonin, 203
 vasopressin, 202
- Transdermal patchess, 319–320
- Transdermal route of drug administration,
 advantages of, 320
- Transepidermal water loss (TEWL), 67, 142,
 166, 232
- Transmission electron micrography (TEM), 96
- Transport partitioning enhancement of CS,
 278
- Transport rate-limiting domain, 286–287
- Treatment of skin cancer
 photodynamic therapy, 205
 radiation therapy, 205
- Trihexyphenidyl hydrochloride (THP), 101
Tripterygium wilfordii Hook F, 129
- Trypsin treatment, 276
- Tumor necrosis, 205
- U**
- U.S. Army Medical Research Institute of
 Chemical Defense, 387–388
- Ultrasound in skin penetration enhancement,
 use of, 258
- Ultrasound low-frequency sonophoresis, 13
- Unsaturated fatty acids, 138–139, 145–146, 148,
 151–154
 effect of, 22f
- Unsaturated fatty alcohols, 142
- USAMRICD, 387–388
- UV absorbers
 2-hydroxy-4-methoxybenzophenone
 (oxybenzone), 375
 2-octyl-4-methoxycinnamate (cinnamate),
 375
- UV filters, 362
- UV protection systems
 molecular UV absorbers, 131
 physical (titanium dioxide), 131
- UV radiation, 131, 373
 filter
 Butyl-methoxydibenzoylmethane
 (BM-DBM), 374
- UVA light, 408
- UV-blockers, 133, 376
- V**
- Vaccine delivery using microneedles, 250
- Validation of INSIGHT, FDC, 327
 efficiency of INSIGHT screening
 enhancement ratio (ER), 327
 formulation incubation period, 327
 measurements in INSIGHT
- Vasoactive intestinal peptide secreting tumors,
 204
- Vehicle effects, 379
- Vehicular penetration retardation, strategies
 cyclodextrins, 374
 encapsulation structures, 374
 photostability, 374
 transcutol[®], 374
- Vesicles and particles, 7–8
- Vesicles under voltage, 257
 combined liposomal and iontophoretic
 delivery, 261–263
 electroporation, 259
 iontophoresis in drug delivery, 258
 iontophoresis, 258
 liposomes and electroporation, 263–265
 liposomes for dermal and transdermal
 delivery, 259–260
 pathways of iontophoretic transport, 258–259
 transfersomes[®] and analogs—
 ultradeformable vesicles, 260
- Vesicles, types of
 transfersomes (ultradeformable liposomes),
 260–261
 traditional vesicles, 261

Veterinary medicine, 406
Volatile solvent, properties, 80; *see*
 Characteristics of solvents enhancers

W

Wide field microscopy, 340
World War I, 386
World War II, 387

X

Xenobiotics on human SC, 294
X-ray scattering, 362

Z

Zwitterionic, 28, 324, 338